Product Name :
Esomeprazole Sodium
Description:
Esomeprazole Sodium, also known as Nexium and H-199, is the S-isomer of omeprazole and acts as a proton pump inhibitor gastric antisecretory agent indicated for the short-term treatment of gastroesophageal reflux disease in patients with a history of erosive esophagitis.
CAS:
161796-78-7
Molecular Weight:
367.40
Formula:
C17H18N3NaO3S
Chemical Name:
sodium 6-methoxy-2-[(S)-(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazol-1-ide
Smiles :
[Na+].CC1=CN=C(C[S@](=O)C2[N-]C3=CC(=CC=C3N=2)OC)C(C)=C1OC
InChiKey:
RYXPMWYHEBGTRV-JIDHJSLPSA-N
InChi :
InChI=1S/C17H18N3O3S.Na/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17;/h5-8H,9H2,1-4H3;/q-1;+1/t24-;/m0./s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Esomeprazole Sodium, also known as Nexium and H-199, is the S-isomer of omeprazole and acts as a proton pump inhibitor gastric antisecretory agent indicated for the short-term treatment of gastroesophageal reflux disease in patients with a history of erosive esophagitis.|Product information|CAS Number: 161796-78-7|Molecular Weight: 367.40|Formula: C17H18N3NaO3S|Synonym:|(S)-Omeprazole sodium|Chemical Name: sodium 6-methoxy-2-[(S)-(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazol-1-ide|Smiles: [Na+].CC1=CN=C(C[S@](=O)C2[N-]C3=CC(=CC=C3N=2)OC)C(C)=C1OC|InChiKey: RYXPMWYHEBGTRV-JIDHJSLPSA-N|InChi: InChI=1S/C17H18N3O3S.Na/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17;/h5-8H,9H2,1-4H3;/q-1;+1/t24-;/m0./s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 100 mg/mL (272.18 mM; Need ultrasonic)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Esomeprazole (25-100 µM; 20 hours; MDA-MB-468 cells) treatment suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification.{{Magrolimab} MedChemExpress|{Magrolimab} CD47|{Magrolimab} Biological Activity|{Magrolimab} In Vitro|{Magrolimab} manufacturer|{Magrolimab} Epigenetics} |In Vivo:|Esomeprazole (30-300 mg/kg; oral gavage; daily; for 19 or 11 days; C57BL/6J mice) treatment significantly inhibits the progression of fibrosis throughout the lungs of the animals.{{Epirubicin} web|{Epirubicin} DNA/RNA Synthesis|{Epirubicin} Biological Activity|{Epirubicin} Description|{Epirubicin} manufacturer|{Epirubicin} Epigenetic Reader Domain} Esomeprazole also reduces circulating markers of inflammation and fibrosis.PMID:23849184 |References:|Wayne Goh, et al. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study. J Pharm Pharm Sci. 2014;17(3):439-46.Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330.Christina Nelson, et al. Therapeutic Efficacy of Esomeprazole in Cotton Smoke-Induced Lung Injury Model. Front Pharmacol. 2017 Jan 26;8:16.Products are for research use only. Not for human use.|
